PT-141

Also known as: Bremelanotide, Vyleesi

Sexual HealthFDA Approved (Vyleesi for HSDD)Subcutaneous

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder. Works on the central nervous system rather than the vascular system.

Molecular Weight

1025.2 Da

Half-Life

~2.7 hours

Sequence

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Mechanism of Action

Activates MC3R and MC4R melanocortin receptors in the hypothalamus, stimulating sexual arousal pathways in the CNS.

Dosing Protocol

500-1500 mcg subcutaneous, 45 minutes before activity. Max once per 24 hours, max 8 doses/month.

Open peptide calculator

Reconstitution

10mg vial + 2mL BAC water = 5000 mcg/mL.

Storage

Lyophilized: -20°C. Reconstituted: 2-8°C.

Side Effects

●Nausea (common)
●Flushing
●Headache
●Skin darkening with repeated use

Key Research Findings

●FDA-approved as Vyleesi for HSDD in premenopausal women
●Effective in both male and female arousal in clinical trials
●CNS-mediated mechanism unlike PDE5 inhibitors

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.